NRC

Business Context and Reporting Period

Company: National Research Corporation (NRC Health)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: NRC Health provides analytics and insights to healthcare organizations to improve patient and employee experiences. The company operates primarily through subscription-based service agreements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 3% year-over-year for both the quarter and the six-month period. The decline was driven by a reduction in U.S. recurring revenue from the existing client base, with non-core solutions accounting for a portion of the decrease.
• Expense Management: Selling, general, and administrative (SG&A) expenses decreased by 6% (quarter) and 5% (YTD) due to workforce reductions, automation, and share-based compensation forfeitures implemented in 2023.
• Interest Expense: Total other expense increased significantly due to higher interest costs from borrowings on the Line of Credit and Delayed Draw Term Loan, offset by lower interest income from reduced money market fund investments.
• Recurring Contract Value: Declined 6% to $138.4 million, attributed to a lack of new contract growth replacing losses, though retention rates remained consistent.
• Working Capital: The company reported a working capital deficit of $28.8 million as of June 30, 2024, compared to $11.8 million at year-end 2023, primarily due to decreased cash, lower receivables, and increased line of credit borrowings.

Guidance, Outlook, and Risks

• Capital Allocation: Priorities include funding innovation (including AI solutions) and M&A, followed by dividends and share repurchases. The company paid $5.8 million in dividends YTD.
• Investment Outlook: Management expects SG&A and direct expenses to increase in future quarters due to new leadership hires, product development investments, and AI solution costs.
• Debt Amendment: On August 5, 2024, the company amended its Credit Agreement to extend the Line of Credit maturity to May 2027 and revise interest rates on the Term Loan to a floating rate (SOFR + 235 bps). The amendment also expanded the use of the Delayed Draw Term Loan to include capital expenditures.
• Acquisition: On July 15, 2024, NRC Health acquired Nobl, Inc. for $5.5 million (plus potential earn-out) to expand rounding solutions for healthcare organizations.
• Risks: Key risks include client contract non-renewal, competitive price pressure, cybersecurity threats, and the impact of global conflicts or economic downturns on healthcare spending.

Investor Verification Checklist

• Liquidity Position: Verify the sustainability of operations given the low cash balance ($0.5M) and reliance on the $21M available Line of Credit and $56M Delayed Draw Term Loan.
• Revenue Trends: Monitor the "Recurring Contract Value" metric closely, as the 6% decline indicates potential headwinds in client retention or upselling.
• Debt Covenants: Confirm continued compliance with the fixed charge coverage ratio (1.10x) and cash flow leverage ratio (3.00x), especially given the recent debt amendment and increased interest rates.
• Capital Expenditures: Track the $9.4M spent YTD on CapEx (software and headquarters renovation) against the projected $4.9M remaining for 2024 renovations.
• Acquisition Integration: Review the final purchase price allocation for the Nobl, Inc. acquisition expected in Q3 2024.